NBSE Stock Summary and Trading Ideas (Neubase Therapeutics | NASDAQ:NBSE)

NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.

Neubase Therapeutics trades on the NASDAQ stock market under the symbol NBSE.

As of May 9, 2024, NBSE stock price declined to $0.39 with 47,042 million shares trading.

NBSE has a beta of 1.63, meaning it tends to be more sensitive to market movements. NBSE has a correlation of 0.02 to the broad based SPY ETF.

NBSE has a market cap of $1.46 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, NBSE stock traded as high as $110.20 and as low as $.36.

The top ETF exchange traded funds that NBSE belongs to (by Net Assets): VXF.

NBSE has underperformed the market in the last year with a price return of -89.7% while the SPY ETF gained +27.7%. NBSE has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -41.7% and -7.2%, respectively, while the SPY returned +4.7% and +2.9%, respectively.

NBSE support price is $.38 and resistance is $.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NBSE stock will trade within this expected range on the day.